First, this is the first study to evaluate the predictive value of plasmatic levels of HSP90α at diagnosis in advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy. This evidence concerns the gene PDCD1 and lung carcinoma.